Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Expenses (2021 - 2025)

Stoke Therapeutics has reported Accumulated Expenses over the past 5 years, most recently at $41.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 433.89% year-over-year to $41.0 million; the TTM value through Dec 2025 reached $41.0 million, up 433.89%, while the annual FY2025 figure was $41.0 million, 433.89% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $41.0 million at Stoke Therapeutics, up from $30.1 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $41.0 million in Q4 2025 and troughed at $1.7 million in Q1 2024.
  • A 5-year average of $14.4 million and a median of $13.4 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: plummeted 88.0% in 2024 and later surged 1372.17% in 2025.
  • Year by year, Accumulated Expenses stood at $5.4 million in 2021, then skyrocketed by 192.55% to $15.7 million in 2022, then dropped by 12.27% to $13.8 million in 2023, then plummeted by 44.36% to $7.7 million in 2024, then skyrocketed by 433.89% to $41.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for STOK at $41.0 million in Q4 2025, $30.1 million in Q3 2025, and $25.6 million in Q2 2025.